R&D News | pharmaphorum

News

Regeneron seeks CheckMate in immuno-oncology play

Regeneron has agreed an all-cash deal to acquire CheckMate Pharmaceuticals, adding immune activator vidutolimod to its cancer immunotherapy pipeline and ending a barren spell for M&A in

News

Doctor using mobile smart phone, work on laptop computer with notebook and medical stethoscope on the desk at office. Telehealth, telemedicine or medic tech concept.

Thread builds in decentralised trials again with CureClick b...

Just over a year after partnering on a project to accelerate recruitment into decentralised clinical trials (DCTs), Thread and CureClick have decided to formally tie the knot.

News

End of the line for BMS, Nektar's bempegaldesleukin/Opdivo a...

Four years after Bristol-Myers Squibb paid $1.85 billion upfront to make Nektar's bempegaldesleukin a companion drug to its cancer immunotherapy Opdivo, the alliance is being discontinued.<

News

Young lonely man in a wheelchair on a balcony looking at the nature in the spring

Sarepta DMD rival PepGen files $115m IPO

Just days after dosing its first patient in a Duchenne muscular dystrophy trial, US biotech PepGen has pushed the button on an initial public offering (IPO).

News

Genmab and AbbVie prep filings for lymphoma bispecific

Two years after signing a $3.9 billion alliance with Genmab to find new cancer therapies, AbbVie has said it is ready to start talking to regulators about filing for approval of the lead dr

News

AACR: AbbVie says mid-stage trial backs navitoclax in myelof...

AbbVie's BCL-2 inhibitor navitoclax has reported phase 2 results in a trial involving rare and hard-to-treat blood cancer myelofibrosis, eyeing an indication not addressed with Venclexta, i

Regeneron seeks CheckMate in immuno-oncology play

Thread builds in decentralised trials again with CureClick b...

End of the line for BMS, Nektar's bempegaldesleukin/Opdivo a...

Sarepta DMD rival PepGen files $115m IPO

Genmab and AbbVie prep filings for lymphoma bispecific

AACR: AbbVie says mid-stage trial backs navitoclax in myelof...

Danco fights back after US court curbs abortion pill access

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks